Silence Therapeutics plc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SLN in the last 30 days.
See all $SLN insider activity →Roche expanded its ADC partnership with Hansoh Pharma, with a deal potentially worth over $15B. Merck KGaA agreed to acquire Silence Therapeutics for $1.3B, gaining a rare blood cancer therapy and RNA tech. Retail sentiment on Stocktwits was neutral for Gilead and bullish for Merck KGaA, Silence Therapeutics, and others.
Disc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.
Amazon (AMZN) rose 4.98% after Morgan Stanley raised its price target to $350, citing AWS growth. Cleveland-Cliffs (CLF) gained 16.05% on Q3 earnings beat. Disc Medicine (IRON) surged 38.86% on positive trial results. Silence Therapeutics (SLN) soared 125.58% after Merck agreed to acquire it for $1.3B. EyePoint (EYPT) plunged 85.28% on trial failure and layoffs.
Over the past 7 days, AlphAI's AI scored 22 news stories mentioning SLN (Silence Therapeutics plc). Coverage has skewed bullish: 21 bullish, 1 neutral, and 0 bearish.
Recent SLN coverage spans mergers & acquisitions, financial news and corporate actions.
Acquisition adds late‑stage rare‑disease asset and RNA tech.
Acquisition announcement drives strong upside momentum.
Acquisition premium drives sharp price increase.
Deal adds a significant premium to Silence's valuation and is likely to drive the stock higher pending closing.
Share price likely to keep rising as the deal closes, with premium pricing baked in.
AlphAI scores every news story that mentions SLN with an AI model for sentiment and relevance, and aggregates insider trades from Silence Therapeutics plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Roche expanded its ADC partnership with Hansoh Pharma, with a deal potentially worth over $15B. Merck KGaA agreed to acquire Silence Therapeutics for $1.3B, gaining a rare blood cancer therapy and RNA tech. Retail sentiment on Stocktwits was neutral for Gilead and bullish for Merck KGaA, Silence Therapeutics, and others.
2 min readDisc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.
2 min readAmazon (AMZN) rose 4.98% after Morgan Stanley raised its price target to $350, citing AWS growth. Cleveland-Cliffs (CLF) gained 16.05% on Q3 earnings beat. Disc Medicine (IRON) surged 38.86% on positive trial results. Silence Therapeutics (SLN) soared 125.58% after Merck agreed to acquire it for $1.3B. EyePoint (EYPT) plunged 85.28% on trial failure and layoffs.
3 min readSilence Therapeutics (SLN) agreed to a $1.3B all-cash takeover by Merck KGaA, representing a 130% premium. The deal focuses on Silence's RNA-based drug platform, including treatments for polycythemia vera and cardiovascular disease. The transaction is expected to close in Q1 2027, pending regulatory approval.
2 min readBiotech stocks rallied on Monday, with Silence Therapeutics (SLN) up 125% after a $1.3B acquisition by Merck, SCWorx (WORX) up 105% on a new healthcare deal, and Disc Medicine (IRON) up 41% on positive trial results. Actinium (ATNM) and Evaxion (EVAX) also saw gains on clinical updates.
2 min readRenforth Resources found significant mineralization at its Quebec deposit. Amazon rose 5% after Morgan Stanley raised its target to $350. Silence Therapeutics surged 59% on a $1.3B Merck takeover. Disc Medicine jumped 38% after positive trial results. Intel gained 5% in a sector recovery. Cleveland-Cliffs expects $4B EBITDA in 2027. Gelion and Petro Matad rose on tech and energy news.
3 min readSilence Therapeutics plc (SLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany All-Cash Transaction Values Silence Therapeutics at Approximately $1.3 Billion Price of$20.00 Per ADS in Cash Represents 130% Premium to Silence’s Closing ADS Price on October
2 min readSilence Therapeutics (SLN) presented updates on its lead drug, divesiran, at the Cantor Fitzgerald Global Healthcare Conference. Phase II data showed strong response rates in polycythemia vera, with 90% at 6 mg every 6 weeks and 88% at 6 mg every 12 weeks. The company raised $200 million, ending Q2 with $72 million in cash, providing a 2.5-3 year runway. Management is preparing for Phase III discussions and weighing partnership options amid rising competition. SLN also highlighted other pipeline
3 min readInvesting.com, citing Macquarie data for the week ended Aug. 14, reports global biotech funding up 75% year over year. IPOs rose 224% and follow-ons 140%, while private investment in public equity rose 29% and venture funding 38%. Examples include Jazz Pharmaceuticals’ $820M upfront deal for Actio Bio and Silence Therapeutics’ $200M upsized IPO.
6 min readSilence Therapeutics plc (Nasdaq: SLN) said it closed an underwritten public offering of 14,907,407 American Depositary Shares at $13.50 per ADS, including full exercise of the underwriters’ option for 1,944,444 additional ADSs. Gross proceeds were about $201.3 million before fees. Joint book-runners were Jefferies, Morgan Stanley, Cantor and William Blair.
2 min read
